Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of HEPA-EN (entecavir 0.5 mg) vs Baraclude (entecavir 0.5 mg) under fasting conditions in healthy adults
TCTR20201109006Phase 1Not yet recruiting
- Sponsor
- Government Pharmaceutical Organization
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Government Pharmaceutical Organization. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on TCTR20201109006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20201109006.